Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis

Edeline, Julien, Lamarca, Angela, McNamara, Mairead G, Jacobs, Timothy, Hubner, Richard A, Palmer, Dan ORCID: 0000-0002-7147-5703, Koerkamp, Bas Groot, Johnson, Philip ORCID: 0000-0003-1404-0209, Guiu, Boris and Valle, Juan W (2021) Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. CANCER TREATMENT REVIEWS, 99. 102258-.

Text Syst review locoregional iCC manuscript v2.docx - Author Accepted Manuscript Download (681kB)

Abstract

<h4>Background</h4>Locoregional treatments (LRT) including radioembolisation (SIRT), transarterial chemo-embolisation (TACE), hepatic arterial infusion (HAI) of chemotherapy, external beam radiotherapy (EBRT) and ablation have been studied for the management of intrahepatic cholangiocarcinoma (iCC). The aim of this systematic review was to provide outcome benchmarks for clinical trial design.<h4>Methods</h4>Identification of studies reporting outcomes of patients treated with LRT for iCC was performed using PubMed and Embase. Pooled weighted means were calculated for progression-free survival (PFS) and overall survival (OS); meta-analysis of proportions was used for estimation of pooled response rate.<h4>Results</h4>6325 entries were reviewed; 93 studies were eligible, representing 101 cohorts and 3990 patients: 15 cohorts (645 patients) for ablation, 18 cohorts (541 patients) for EBRT, 27 cohorts (1232 patients) for SIRT, 22 cohorts (1145 patients) for TACE, 16 cohorts (331 patients) for HAI and 3 cohorts (96 patients) not pooled. 74% of the studies were retrospective, 99% non-randomised. The pooled mean weighted OS was 30.2 months (95% confidence interval (CI): 21.8-38.6) for ablation, 18.9 (14.2-23.5) for EBRT, 14.1 (12.1-16.0) for SIRT, 15.9 (12.9-19.0) for TACE and 21.3 (15.4-27.1) for HAI. The pooled complete response rate was 93.9% for ablation. When analysed together, SIRT, TACE and HAI had a pooled mean weighted OS of 15.7 months, and 25.2 months for patients treated in first-line with concomitant systemic chemotherapy.<h4>Conclusions</h4>Available literature on LRT for iCC was heterogeneous and of insufficient quality to make strong recommendations. Ablation achieved satisfactory outcomes, and may be recommended when surgery is not feasible.

Item Type:	Article
Uncontrolled Keywords:	Yttrium-90, Intra-arterial therapies, Biliary tract cancer, Interventional radiology, Interventional oncology, Radiation oncology
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	02 Aug 2021 09:54
Last Modified:	18 Jan 2023 21:35
DOI:	10.1016/j.ctrv.2021.102258
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3131583